Segal NH, et al. – In this study, researchers evaluated the safety and efficacy of durvalumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). They administered 10 mg/kg of durvalumab intravenously to study participants (n=62) every 2 weeks for 12 months or until confirmed progressive disease or unacceptable toxicity. In line with other cohorts of the study, durvalumab safety profile in HNSCC was manageable. The investigators noted all-causality adverse events (AEs) in 98.4% of patients. A total of 59.7% displayed drug-related AEs and were grade 3-4 in 9.7%. No drug-related discontinuations or deaths were noted. They recorded median progression-free survival of 1.4 months and median overall survival (OS) of 8.4 months. At 6 months and 12 months, OS rates were 62% and 38%, respectively.